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a b s t r a c t
Background and purpose: Proton therapy is expected to outperform photon-based treatment regarding
organs at risk (OAR) sparing but to date there is no method to practically measure clinical benefit.
Here, we introduce the novel ROCOCO Performance Scoring System (RPSS) translating dose differences
into clinically relevant endpoints and apply this to a treatment plan comparison of volumetric modulated
arc therapy (VMAT) and intensity modulated proton therapy (IMPT) in 20 pilocytic astrocytoma patients.
Material and methods: The RPSS was developed on the basis of expert-based weighting factors and tox-
icity scores per OAR. The imaging datasets of 20 pilocytic astrocytoma patients having undergone radio-
therapy were included in this in silico dosimetric comparison trial as proof of principle. For each of these
patients, treatment plans to a total dose of 54 Gy (RBE) were generated for VMAT and IMPT and these
were compared regarding radiation dose to the clinical target volume (CTV) and OARs. The RPSS was cal-
culated for each treatment plan comparing VMAT and IMPT.
Results: In 40 analysed treatment plans, the average and low dose volumes to various OARs were signif-
icantly reduced when using IMPT compared to VMAT (p < 0.05). Using the RPSS, a significant difference
between both treatment modalities was found, with 85% of the patients having a lower RPSS in favour of
the IMPT plan.
Conclusion: There are dosimetric differences between IMPT and VMAT in pilocytic astrocytoma patients.
In absence of clinically validated NTCP models we introduce the RPSS model in order to objectively com-
pare treatment modalities by translating dosimetric differences in potential clinical differences.
 2021 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Proton therapy as radiation treatment modality has been intro-
duced in the last decade and is currently available in many coun-
tries. It may have an advantage over photon therapy due to its
physical properties which allows sparing of organs at risk (OARs)
situated behind the tumour [1]. It is known that radiation dose
to the brain in long term brain tumour survivors can lead to irre-
versible cognitive decline, directly affecting the patient’s quality
of life [2]. Multiple studies have already shown a dosimetric advan-
tage of proton therapy in this patient group [3,4,5,6,7]. These stud-
ies report significantly reduced low dose volumes using intensity
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modulated proton therapy (IMPT) compared to volumetric arc
photon therapy (VMAT). However, the clinical benefit of these
reduced low dose volumes remains unclear. To our knowledge,
there is no system available to translate these dosimetric differ-
ences in clinical relevant endpoints.
Due to the recent availability of proton therapy in the Nether-
lands with a maximum of 2200 patients per year, the model based
approach has been adopted to decide whether a patient is a candi-
date for proton therapy depending on the clinical relevance of the
dose reduction to the OARs in a photon versus proton treatment
plan comparison. A 10% reduction in grade 2 toxicity is required
using a validated photon based normal tissue complication proba-
bility (NTCP) model in order to become eligible for proton therapy
[8]. Unfortunately, there are currently no externally validated
NTCP models available for central nervous system (CNS) OARs
including those related to cognition. Therefore, in The Netherlands,
a  5% dose benefit in the mean dose (Dmean) hippocampi and/or
supratentorial Brain minus the clinical target volume (CTV) is cur-
rently adopted as indication for the use of proton therapy, resulting
in reimbursement by the health insurance. Until now, no scoring
system exists which incorporates all available OARs, resulting in
a uniform selection tool until CNS NTCP models become available.
In this paper we introduce the Radiation Oncology Collaborative
Comparison Group (ROCOCO) Performance Scoring System (RPSS),
which is an assessment of a radiation treatment plan using
weighted scores of differences in dose to OARS (Ddose). The pur-
pose of the RPSS is to translate dose differences into a score which
reflects expected overall toxicity burden. This score can help clin-
icians in deciding whether patients will benefit from particle ther-
apy. In order to demonstrate the power of the RPSS, we assessed
dosimetric differences and the associated RPSS scores of VMAT
and IMPT plans in an example dataset consisting of 20 pilocytic
astrocytoma patients.
2. Materials and methods
2.1. ROCOCO performance scoring system
In order to compare treatment plans on an individual patient
level, we introduced the ROCOCO Performance Scoring system
based on two components. First, a simplified NTCP table was
defined, based upon the published European Particle Therapy Net-
work dose constraints in neuro-oncology (Fig. 1) [9,10]. A score
was determined in consensus (LV, DE), ranging from 1 to 5, where
1 indicates that no toxicity is expected in this specific OAR in a
dose range, while a score of 5 expresses that severe toxicity is to
be expected. When different dose levels have the same number,
no clinically relevant difference in toxicity is to be expected
between these dose levels.
Secondly, in order to translate dose to OARs into their expected
clinical relevance we introduced a weighting factor for each OAR,
based upon expert opinion (LV, DE, IC, ET), ranging from 0 to 1
(Fig. 1). A high weighting factor (0.7–1) indicates a highly clinically
relevant OAR for expected late toxicities, while a low weighting
factor (0–0.3) indicates a less clinically relevant OAR. Some OARs
were assigned a weighting factor of 0. In these OARs dose limits
are never exceeded thus not expected to induce toxicity.
Each OAR was then scored between 1 and 5 depending on the
dose received in the VMAT and IMPT treatment plan. Next, the
RPSS values for the IMPT and the VMAT treatment plans were
determined by multiplying the NTCP scores, based upon the doses
to the OARs, and the weighting factors for each OAR and summaris-
ing these per patient:
RPSSp ¼ 1N 
XN
i¼1
WFi  NTCPið Þ ð1Þ
with p = patient, N = number of OAR, WFi = weight factor per OAR,
NTCPi = normal tissue complication per OAR
2.2. Study population
The population, on which the RPSS was assessed, consisted of
20 consecutive pilocytic astrocytoma patients treated with radio-
therapy at one of three Dutch university hospitals, the Radboud
University Medical Centre (Radboudumc), Nijmegen, the Univer-
sity Medical Center of Amsterdam (AMC), Amsterdam or the
Department of Radiation Oncology of Maastricht University Medi-
cal Center (MAASTRO), Maastricht. Radiation therapy was either
indicated as primary treatment, after resection or after chemother-
apy. This ROCOCO in silico trial was approved by the MAASTRO
clinic institutional review board.
2.3. Target volume and OAR definition
All patients had a planning CT prior to radiotherapy. For stabil-
isation, each patient received an individual head support and ther-
moplastic mask. The radiation oncologist of each centre delineated
the target volumes using the planning CT after co-registration with
the MRI (T1-weighted with contrast agent and T2-weighted/FLAIR
images). The individual patient’s gross tumour volume (GTV) and
clinical target volume (CTV) were identical for both treatment
options (VMAT, IMPT). The margin for CTV was set at 5 mm for
all patients independent of the original treatment protocol [11].
For VMAT planning, the CTV was expanded with a 2 mm margin
for the planning target volume (PTV), accounting for linear
accelerator-based setup errors chosen uniformly for all centres.
All OARs were outlined by one dosimetrist and supervised by a
radiation oncologist in training and a radiation oncologist (LV and
DE). The following OARs were identified and delineated: brain,
brainstem, optic chiasm, retina, cochlea, optic nerves, spinal cord,
hippocampi, cornea, lacrimal glands, pituitary gland, lens, supra-
tentorial brain, cerebellum, and anterior and posterior cerebellum
[1,12]. A bilateral OAR (e.g. hippocampus, cochlea, cornea) was ter-
med ‘contralateral’ when located outside the CTV and at the con-
tralateral hemisphere. If the tumour was located centrally or
both left and right OARs were situated within the CTV, the OAR
was named ‘bilateral’. Severe dental scatter artefacts or metal den-
tal implants were delineated and the density was overridden to
that of teeth or tissue. Dental fillings within the treatment beam
were an exclusion for IMPT.
2.4. Dose prescription and constraints
The prescribed dose to the target volume was 54 Gy (RBE) tak-
ing into account the factor 1,1 for relative biological effectiveness
(RBE) in proton plans. The dose limits of the OARs were defined
in the study protocol and are listed in Supplementary Table 1. A
prioritisation was made as a guideline and defined in the study
protocol. It was used for planning purposes and not for the weight-
ing factors used to calculate the RPSS.
2.5. Photon and proton planning
The photon VMAT plans were made according to current clini-
cal practice at Maastro clinic, using EclipseTM (v11.0 Varian Medi-
cal Systems, Palo Alto, CA). 99% of the PTV received at least 95% of
the prescribed dose. Cold spots (<95%) and hot spots (>107%) were
avoided and no hot spots were allowed outside the PTV.
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The proton treatment plans were calculated at OncoRay (Dres-
den, Germany) using RayStation (v4.65.99, RaySearch Laboratories
AB, Stockholm, Sweden). IMPT was used for beam delivery utilising
Pencil Beam Scanning (PBS). No PTV concept was used in these
plans. Instead, the plans were robust for target coverage of the
CTV, considering 21 scenarios for the optimisation process, taking
a setup uncertainty of 2 mm and range uncertainty of 3,5% into
account. In order to spare the organs at risk and avoid passing
through air cavities, beam directions (mostly two beams, some-
times three beams) were chosen individually for each single
patient. The beam arrangements did not affect the margin.
2.6. Data evaluation and statistical analysis
For OARs and CTV in each of the VMAT and IMPT plans the
mean dose (Dmean), maximum dose (Dmax) and near-maximum
dose (D2% or D0.1cc, the highest dose to 2% or to 0.1 cc of the volume
of interest, respectively) were calculated [13]. For the hippocam-
pus the D40% was calculated (according to Gondi et al. [14]) For sta-
tistical analysis, the previously described framework was utilised
to centrally extract dose-volume-histograms (DVH) metrics from
the 3D dose distributions of each single radiation treatment plan
using in-house developed software in Matlab (version 2017a, The
MathWorks, Natick, MA) [15]. The VMAT plan was considered
the gold standard. In order to adequately compare both treatment
modalities, the doses to the CTV were evaluated as no PTV was
used for the IMPT treatment plans. Doses were scaled such that
99% of the CTV received exactly 100% of the prescribed dose
[54 Gy (RBE)]. The DVH metrics, doses to OARs, and the RPSS data
were compared using a two-tailed Wilcoxon ranked sum test to
determine the significance of differences between IMPT and VMAT.
We consider a p-value of < 0.05 as statistically significant. In order
to evaluate the conformity of the CTV coverage in combination
with dose to the normal tissue we used the Van ‘t Riet Conformity
Number with 1 indicating a perfect conformity [16].
3. Results
3.1. Plan comparison
In total, 40 treatment plans (20 VMAT, 20 IMPT) of 20 consecu-
tive pilocytic astrocytoma patients treated with radiotherapy in
the age of 2–21 years were calculated and analysed. Overall, the
coverage of the CTV was excellent for both modalities, with a vol-
ume receiving 95% (V95%) for the CTV54Gy of 97.7% for IMPT and 98,
5% for VMAT. The dose coverage of the CTV54Gy was significantly
higher for the VMAT plans compared to the IMPT plans. Table 1
shows the average scaled Dmean, D40% and D2% for all of the OARs
in the IMPT treatment plans compared to the VMAT treatment
plans.
Overall, the D2% was significantly lower in 7/12 (58%) OARs for
the IMPT plans compared to the VMAT plans. For the Dmean, 9/11
(82%) OARs received significantly less radiation dose when planned
with IMPT. The D40% of the hippocampus was significantly lower in
the IMPT treatment plans, for both the ipsi- and bilateral as con-
tralateral hippocampus. Fig. 2 shows a comparison of the percent-
ages of volume of the brain minus the CTV, hippocampus ipsi- and
bilateral, hippocampus contralateral, posterior cerebellum and
supratentorial brain minus the CTV receiving a dose up to 50 Gy
(V10Gy – V50Gy). It can be seen that for all these OARs the low dose
volumes were statistically significantly reduced using IMPT
whereas the high dose volumes were comparable or increased
when IMPT was compared with VMAT. The mean integral dose to
the body was statistically significantly decreased for IMPT (4,5
Gy) compared to VMAT (6,5 Gy), with p < 0.05.
3.2. RPSS
The summed weighted RPSS toxicity score for each modality per
individual patient is presented in Fig. 3. In 17/20 (85%) patients,
IMPT received a superior (lower) score compared to VMAT. In
2/20 (10%) patients, the score was identical and in 1/20 (5%)
Fig. 1. Simplified normal tissue complication probability (NTCP) table based upon the published European Particle Therapy Network dose constraints in Neuro oncology, data
in adults [9,10].
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patients, VMAT received a superior score of 0.228 compared to
0.235 for IMPT, where all expected toxicities were equal except
for the posterior cerebellum minus the CTV which received a
higher dose. Overall, the RPSS data for IMPT and VMAT proved sta-
tistically significantly different in favour of the IMPT group with a
p-value of 0.00023. Fig. 4 shows the delivered doses for specific
OARs in patients 9 and 12. Patient 9 had an RPSS in favour of IMPT,
which is showed by the plot. In this case, the pituitary gland
received an equally high dose with both modalities, all other
organs received a lower dose with IMPT, thus resulting in a better
RPSS. Patient 12 had an equal RPSS for IMPT and VMAT. The lacri-
mal gland and pituitary gland received less dose in the IMPT plan,
however, the supratentorial brain and hippocampi received equal
dose and due to the weighting factors the RPSS score was conse-
quently equal.
4. Discussion
In our study, we found that IMPT was superior in sparing most
OARs compared to VMAT. In an attempt to translate the dosimetric
differences found in this study into clinically relevant endpoints
we compared IMPT and VMAT treatment plans by introducing
the RPSS based on expected toxicity for organs at risk. There was
a significantly reduced RPSS for IMPT plans in 17/20 patients,
meaning less toxicity can be expected in these plans.
The RPSS is a novel scoring system and an example of how a
practical scoring can help a clinician in deciding which treatment
plan is most beneficial for the patient regarding possible long-
term side effects. The dataset used in this study consisted of 20
pilocytic astrocytoma patients. Pilocytic astrocytoma is a rare diag-
nosis predominantly seen in children [17]. Only a very small subset
of children with this diagnosis undergo radiation therapy. It is
important to notice that this pilocytic astrocytoma dataset was
only used as an example to explain the mechanism and power of
the RPSS. The toxicity data used for the RPSS was based on treat-
ment in adults, so the RPSS as shown in this study is only applica-
ble in adults receiving cranial radiation for brain tumors. Although
the RPSS is presented in brain tumor patients in this article, the
same principle is applicable to all tumor types and comparison of
all types of treatment modalities.
There are a few important limitations of the RPSS. The weights
of the scoring factors have a big impact on the total score of the
RPSS. No data exist yet on how these weight factors should opti-
mally be determined. The Neuro OAR weighting table (Fig. 1) that
was used for the RPSS was based upon the European Particle Ther-
apy Network (EPTN) OAR CNS consensus tolerance table which is
extracted from an extensive literature search and is not yet exter-
nally validated requiring continuous optimization [9]. The weight
factors used in this study were decided upon after consensus
between only 4 CNS radiation oncologists. And the score from 1
to 5 are big steps and maybe not detailed enough, which may have
influenced the final outcomes. The same applies for the weighting
factors. If other choices were to be made for the weighting factors,
outcomes could be different. This does however reflect current
practice internationally because there is no objective scoring sys-
tem available. Another limitation of the RPSS is that not all poten-
tial relevant factors are incorporated into the RPSS system, such as
age and location of the tumor. The RPSS is an overall indication
whether less or more toxicities can be expected from an overall
treatment plan. It is for the clinician to decide which toxicity is
important in an individual patient and take all OARs into account
before deciding which treatment modality is most suitable for that
patient. There is no differentiation between treatable toxicities and
non-treatable toxicities in the current version of the RPSS. It was
decided to score untreatable and treatable toxicities. One could
argue to score only the untreatable toxicity for example resulting
in cognitive decline. Radiation therapy can cause late cognitive
decline caused by damaging the brain by several mechanisms such
as inducing vascular damage, demyelination and white matter
changes to certain parts of the brain [18,19,20,21]. Although
recently the OARs identified as possibly being relevant to cognition
are expanded, future research needs to show if other areas in the
brain should be taken into account and delineated when treating
a CNS tumour [20]. For example, in the current version of the RPSS
the choice was made to give several OARs a weighting factor of 0
based upon the fact that dose limits in these important OARs such
as the brain are never exceeded thus not expected to induce toxi-
city. However, a recent randomized phase II trial shows that the
Brain V20Gy was a strong predictor for severe lymphopenia in
patients treated with radiation and temozolomide for glioblastoma
[22]. In our study a RBE of 1.1 for proton therapy was used. How-
ever, there is an increasing uncertainty at the end of the Bragg peak
which may lead to a higher value at the distal end [23]. This may
affect the calculated RPSS score and needs further exploration in
the future.
All of the above limitations show that the RPSS is a proof of
principle for now. Future research and data will make optimization
of the RPSS possible. In order to implement the RPSS clinically, a
broader international concensus is necessary, preferably within
the European Particle Therapy Network (EPTN). When imple-
mented, we still expect alterations to the RPSS as new data become
available, making it a dynamic process.
Table 1
Dose and coverage parameters per organ at risk or target volume for VMAT and IMPT.
Organs at risk VMAT D2% IMPT D2%
Brain 55.1 (4.6) 54.9 (1.3)
Brainstem 51.3 (16.3) 50.9 (17.0)
Optic chiasm 31.8 (23.1) 26.1 (27.4)
Cornea ipsi and bilateral 10.1 (8.0) 4.4 (7.1)*
Cornea contralateral 4.3 (3.8) <0.01 (<0.01)*
Lens ipsi and bilateral 3.5 (2.9) 0.96 (1.9)*
Lens contralateral 1.9 (2.4) <0.01 (<0.01)*
Optic nerve ipsi and bilateral 30.8 (23.9) 28.3 (26.6)
Optic nerve contralateral 8.2 (6.8) 0.065 (0.16)*
Retina ipsi and bilateral 12.2 (10.0) 7.5 (11.5)*
Retina contralateral 4.6 (4.2) <0.01 (<0.01)*
Spinal cord 7.7 (17.0) 10.5 (18.5)
Organ at risk VMAT D40% IMPT D40%
Hippocampus ipsi and bilateral 17.6 (14.7) 11.4 (16.0)*
Hippocampus contralateral 5.6 (3.6) 1.0 (1.7)*
Organs at risk/target volume VMAT Dmean IMPT Dmean
Brain 11,2 (3.9) 7.9 (3.0)*
Cerebellum anterior – CTV 26.5 (11.2) 15.2 (15.0)*
Cerebellum posterior – CTV 17.6 (10.9) 10.7 (12.9)
Cochlea ipsi and bilateral 14.3 (9.6) <0.01*
Cochlea contralateral 6.0 (6.0) 0.071 (0.065)*
Hippocampus ipsi and bilateral 17.2 (12.8) 11.1 (12.8)*
Hippocampus contralateral 5.7 (3.9) 1.7 (3.2)*
Lacrimal gland ipsi and bilateral 8.8 (7.5) 3.3 (5.8)*
Lacrimal gland contralateral 3.7 (3.7) <0.01 (<0.01)*
Supratentorial brain – CTV 9.3 (4.3) 6.5 (3.8)*
Pituitary gland 26.5 (24.2) 23.4 (26.4)
Integral dose to the body 6.5 (2.5) 4.5 (2.1)*
CTV54Gy 57.2 (2.4) 55.6 (2.0)*
GTV 57.0 (2.5) 55.4 (1.9)*
CN VMAT D95% IMPT D95%
CTV54Gy 0,62 (0.068) 0,57 (0.11)*
D2%: dose to 2% of the volume reported in Gy(RBE); D40%: dose to 40% of the
volume reported in Gy(RBE); Dmean: mean dose to organ at risk or target volume in
Gy(RBE); D95%: dose to 95% of the volume reported in Gy(RBE) CTV54Gy: Volume
of the CTV receiving 54 Gy; CN: conformity number. Numbers between parentheses
are standard deviations. * numbers with asterisk are statistically significantly dif-
ferent (p < 0.05).
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Fig. 2. The percentage of organs at risk volume receiving a radiation dose between 10 Gy and 50 Gy (V10Gy to V50Gy, respectively); A: contralateral hippocampus, B: ipsilateral



















Fig. 3. Differences in RPSS scores for VMAT (blue) and IMPT (red) plans for each patient. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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The fact that IMPT was superior in sparing most OARs in this
dataset is in line with other studies. Eekers et al. [3] compared four
treatment modalities (IMRT, VMAT, TOMO and IMPT) in low grade
glioma and found a significantly reduced low-dose volume when
using IMPT. Toussaint et al. also found that the distribution of
doses to brain substructures associated with cognition are consis-
tently lower with proton therapy [24]. Only a few studies reported
on neurocognitive outcomes of proton therapy versus photon ther-
apy in patients receiving cranial radiation. Gross et al. [25] reported
on 125 paediatric brain tumour survivors who received cranial
radiation with either photon or proton therapy. The proton therapy
group had higher IQ scores and better scores on processing speed
compared to the photon group. This is in line with the findings
of Kahalley et al. [26] who examined changes in IQ scores over time
in a group of patients (n = 150) who received cranial radiation
comparing photon therapy with proton therapy. While the proton
group did not show IQ changes over time, the IQ declined with 1.1
points per year in the photon group. Recently, Dutz et al. [27]
reported on 62 brain tumour patients treated with proton therapy
who’s neurocognition was assessed three-monthly using the Mon-
treal cognitive assessment (MoCa). Overall, the MoCa score and
self-reported cognitive function remained stable over time.
Patients with declined scores experienced more physical and cog-
nitive deficits compared to patients without decline in scores. In
this study slight deterioration of MoCa score was associated with
tumours located in the left hemisphere and increase of volume of
the anterior cerebellum that received 30–40 Gy (RBE).
It is known that radiation dose to the brain can lead to mostly
irreversible cognitive decline, directly affecting the patient’s daily
functioning [2]. This cognitive decline develops over many years
and the severity can be influenced by multiple factors such as
age, use of chemotherapy, shunting procedures, surgeries and the
tumour itself [19,28]. So, individual patient characteristics could
also be assumed relevant and were not yet taken into account in
the RPSS. At which doses levels the damage mechanisms occur
remains unclear, so whether avoiding a low dose bath to the organs
at risk will eventually translate into a clinically relevant benefit
also remains subject of future research. As mentioned earlier, we
found a statistically significant decrease of the integral dose to
the body in favour of IMPT. A major concern of increase in low-
dose volumes, especially in paediatric patients, is induction of sec-
ondary malignancies [29,30,31]. Theoretically, IMPT should lead to
a decreased risk of induction for secondary tumours. However, the
dose–response relationship for induction of secondary cancers has
been much debated and there are no validated models to predict
the absolute reduction of risk for protons versus photons.
5. Conclusion
The novel ROCOCO Performance Score (RPSS) was developed
and introduced to translate dosimetric differences in clinically rel-
evant benefits. In this study, the RPSS showed a benefit of IMPT
over VMAT in the majority of patients in our pilocytic astrocytoma
dataset. The RPSS is a proof of principle and can be used in all types
of treatment modalities in different types of tumors using the
appropriate toxicity scores and weighting factors. It is a first step
towards a uniform practical scoring system which is necessary
for clinical decision making in proton therapy. In order to optimize
the RPSS, registration of late toxicity is obligatory for example in
the national Dutch database Proton therapy research infrastructure
(PROTRAIT) in order to correlate dose to CNS toxicity. Future stud-
ies and international consensus are essential to evaluate, improve
and correlate, the RPSS to patient treatment outcome, overall tox-
icity and the potential benefit of proton treatment.
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Fig. 4. Logarithmic plots of differences in Dmean, D0.03cc and D40% per OAR (x weighting factor) for IMPT and VMAT plans for patient 9 (A) and patient 12. (B) The white border
of the plot represents the dose constraint.
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